Medera Doses First Patient in AAV Gene Therapy Trial for DMD Cardiomyopathy

Jul 15 , 2025
share:

BOSTON and KANSAS CITY, Kan. – July 15, 2025 – Medera Inc. and its Sardocor division, in collaboration with the University of Kansas Medical Center, today announced the successful treatment of the first patient in the MUSIC-DMD Phase 1b clinical trial. This marks a pivotal step for AAV1.SERCA2a, a one-time AAV gene therapy targeting cardiomyopathy secondary to Duchenne muscular dystrophy (DMD-CM).

The patient received the treatment via Medera’s proprietary minimally invasive intracoronary infusion methodology through the left radial artery, tolerated the procedure well, and was discharged overnight.

Medera CEO Ronald Li, PhD, emphasized that addressing DMD-CM, now the leading cause of mortality in DMD patients, is a critical unmet need. AAV1.SERCA2a aims to restore calcium handling in heart muscle cells, potentially reversing disease progression in a condition characterized by calcium overload. Dr. Pradeep Mammen, the study’s principal investigator, highlighted the therapy’s innovative approach to fundamental calcium handling defects. Pat Furlong of PPMD noted its promise for “repairing hearts” in Duchenne, a disease affecting over 300,000 people globally with limited current cardiac treatments.

Source:

https://www.globenewswire.com/news-release/2025/07/15/3115530/0/en/Medera-and-University-of-Kansas-Medical-Center-Announce-First-Patient-Treated-in-Pioneering-Gene-Therapy-Trial-for-Duchenne-Muscular-Dystrophy-Associated-Cardiomyopathy.html

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download

Login

Don't have an account? Please register
Account*
Password*
Code*
Refresh
Forgot password?
Logging in indicates that you have read and accepted the Registration Agreement and User Agreement
Log in with other accounts

New User Registration

Already have an account?
First Name*
Middle Name
Last Name*
Organization*
Organization Type*
Country/State*
Email Address*
Code*
Set Password*
Confirm password*
Refferal Code*

Reset Password

Return to
Email*
Code*
New password*
Confirm password*

Google Account Binding

Organization*
Organization Type*
Country/State*